The circuit begins at the Maxim Growth Summit in New York City on October 14. The following day, Cooper shifts to the ThinkEquity Conference, where he will present findings on Nu-3, a broad-spectrum antimicrobial compound designed to combat resistant pathogens, specifically targeting infected diabetic foot ulcers.
His final stop lands in Washington, D.C., on October 22 for IDWeek. At this event, Cooper will present a poster detailing new preclinical data regarding the Nu-3 candidate. These appearances underscore the company’s push to advance its proprietary Bisphosphocin class, which is currently being developed to address persistent bacterial threats like MRSA and VRE.
Comments (0)
No comments yet. Be the first!